ENTX
$1.38
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs.
Recent News
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
Opko Health Inc. (NASDAQ:OPK) is one of the best high-return penny stocks to buy right now. On February 10, analysts at H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) and settled on a $3 price target. The positive stance underscores the research firm’s confidence amid progress in the company’s biological partnerships. The […]
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development
Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replacement therapies, to advance the first oral long-acting PTH analog (LA-PTH) treatment for patients with hypoparathyroidism, in […]
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Individual investors are Entera Bio Ltd.'s (NASDAQ:ENTX) biggest owners and were rewarded after market cap rose by US$34m last week
Key Insights The considerable ownership by individual investors in Entera Bio indicates that they collectively have a...
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.